■溃疡性结肠炎(UC)引起消化道慢性炎症,导致腹痛和腹泻。阿达木单抗,单克隆抗体,用于治疗中度至重度病例。本综述和荟萃分析评估了阿达木单抗治疗重度UC的有效性。考虑到患者年龄,疾病持续时间,和性别。
■本研究设计为系统综述和荟萃分析。文章在PubMed中搜索,Scopus,以及基于阿达木单抗和UC关键词的WebofScience数据库。标题,摘要,and,如有必要,阅读了文章的全文。然后进一步审查,仔细研究了相关文章的全文,最后的文章被选中。根据关键字搜索了78篇文章,在阅读了文章之后,50篇文章与论文的主题有关。根据统计顾问准备的清单对50篇文章进行了严格评估,并选择了四篇得分超过70%的文章。在这四篇文章中,阿达木单抗有效性的主要指标,包括粘膜愈合,临床缓解,和临床反应,进行了评估。
■阿达木单抗对黏膜愈合指数的有效率为75.40%,临床缓解指数为70.79%,临床反应指数为83.02%,根据研究中的不同剂量和治疗持续时间。在关于阿达木单抗有效性的四项荟萃分析研究中,1613例UC患者接受了8周和52周不同剂量的治疗。基于8周和52周治疗中度至重度UC的荟萃分析,阿达木单抗的有效性为70%-83%。效率最高,基于三个主要指数,在52周内服用40毫克剂量。
■根据荟萃分析,阿达木单抗治疗中重度UC超过8周和52周的有效性为70%-83%.效率最高,基于三个主要指数,在52周内服用40毫克剂量。
UNASSIGNED: Ulcerative colitis (UC) causes chronic inflammation in the digestive tract, leading to abdominal pain and diarrhea. Adalimumab, a monoclonal antibody, is used to treat moderate to severe cases. This
review and meta-analysis evaluated adalimumab\'s effectiveness for severe UC, considering patient age, disease duration, and gender.
UNASSIGNED: This study was designed as a systematic
review and a meta-analysis. Articles were searched in PubMed, Scopus, and Web of Science databases based on the keywords of adalimumab and UC. The titles, the abstracts, and, if necessary, the full texts of the articles were read. Then for further
review, the full texts of the related articles were carefully examined, and the final articles were selected. Seventy-eight articles were searched based on the keywords, and after reading the articles, 50 articles were related to the topic of the dissertation. The 50 articles were evaluated critically based on a checklist prepared by a statistical consultant and four articles with a score above 70% were selected. In the four articles, the main indicators of the effectiveness of adalimumab, including mucosal healing, clinical remission, and clinical response, were evaluated.
UNASSIGNED: The effectiveness of adalimumab on the mucosal healing index was 75.40%, the clinical remission index was 70.79%, and the clinical response index was 83.02%, based on different doses and treatment durations in the study. In the four meta-analysis studies on adalimumab\'s effectiveness, 1613 UC patients were treated with varying doses over 8 and 52 weeks. Based on a meta-analysis over 8 and 52 weeks for treating moderate to severe UC, adalimumab\'s effectiveness was 70%-83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.
UNASSIGNED: According to the meta-analysis, the effectiveness of adalimumab for treating moderate to severe UC over 8 and 52 weeks was 70%-83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.